Abcodia has launched its ROCA ovarian cancer test in five US states: Arizona, Illinois, Massachusetts, New Jersey, and Texas.
The test, available as a service from the company's testing laboratory, is designed to aid in the early detection of ovarian cancer through the analysis of a number of clinical variables such as age, menopausal status, and serial blood measurements of the biomarker protein CA125. The assay is the first step in a multimodal assessment for ovarian cancer and is to be used to help physicians assess whether a woman should undergo additional testing, including a transvaginal ultrasound scan of the ovaries.
Abcodia said that the test is intended for post-menopausal women between 50 and 85 years old and with no known ovarian cancer risk factors; or women 35 to 85 who are considered to be at high risk of ovarian cancer due to a family history of ovarian or breast cancer, or a mutation in specific genes such as BRCA1, BRCA2, or Lynch syndrome genes.
The test is already being used in the UK by private clinics and will become available in additonal US states throughout 2016, Abcodia said.
For more on the ROCA test, click here.